LiDCO : Launching the new LiDCOunity at ISICEM Brussels

LIDCO GROUP PLC

('LiDCO' or the 'Company' or 'the Group')

LiDCO (AIM: LID), the hemodynamic monitoring company, will be attending the International Symposium on Intensive Care and Emergency Medicine ('ISICEM'), one of the largest trade shows in its field, attracting globally more than 6,200 participants and launch its new LiDCOunityproduct at the event.

LiDCO will be showcasing the Company's products along with the new LiDCOunityat stand 1.07-1.08throughout the trade show which is being held from today to Friday 18 March 2016.

LiDCOunitycombines for the first time the full suite of LiDCO technology into one offering allowing continuous hemodynamic monitoring, including monitoring of level of consciousness across the entire clinical pathway in one monitor.

The advanced monitoring system brings together LiDCOplusand LIDCOrapidscreens and allows seamless monitoring from the Emergency Department to the Operating Room, to the Intensive Care Unit and to other High Dependency Units. LiDCOunityhas the flexibility to meet LiDCO's customer needs as their patient's acuity changes. It also has many key advantages, such as a compact screen size for easy integration around the bedside; the data is maintained from prior monitoring to provide complete history; and it is HL7 compatible for communication with hospital information and electronic patient record systems.

ISICEM is geared towards giving participants an understanding of the most recent, clinically relevant, developments in research and the management of the critically ill which makes it an ideal show to launch the LiDCOunity.

Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: 'The ISICEM is the perfect platform to showcase the new LiDCOunityproduct to our key target audience, and we are excited to be part of one of the industry's largest trade shows. LiDCOunity is a real differentiator and is the first product to enable clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.'

The event is being held at Brussels Meeting Centre, Glass Entrance, rue Mont des Arts, 1000 Brussels, Belgium. For further information, please go to: www.intensive.org

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity:a hemodynamic monitor that combines the full suite of LiDCO technology (LiDCOplus,LiDCOrapidand LiDCOview) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapidprovides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapidallows the LiDCOrapidmonitor to co-display Covidien's level of consciousness parameter ('BIS)* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview: an easy-to-use graphical display of historical LiDCOplusand LiDCOrapidhemodynamic data.

*BIS and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

**CNAP is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USAand through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.

LIDCO Group plc issued this content on 15 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 15 March 2016 07:15:47 UTC

Original Document: http://www.digitallook.com/ir/security.cgi?csi=31227&action=news&story_id=24118895&rns=1